ERS 2026 Preview: Respiratory Therapies and Competitive Trends
ERS 2026 at a glance Will respiratory treatment differentiation increasingly…
ATS 2026 Preview: Emerging Respiratory Medicine Trends and AI
ATS 2026 at a glance ATS 2026 in Orlando highlights emerging developments in…
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…
Respiratory Today—January 23, 2026
This update highlights significant advancements in clinical trials, regulatory…
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…
Respiratory Today—January 9, 2026
This respiratory update spotlights reflects strong momentum across respiratory…
Respiratory Today—December 5, 2025
This week’s respiratory update highlights major developments across RSV…
Respiratory Today—November 28, 2025
Explore this week’s respiratory highlights, including new developments,…
Respiratory Today—November 21, 2025
Discover what’s new in Respiratory this week including regulatory approvals,…
Respiratory Video Recap—November 14, 2025
This respiratory video recap spans late-stage trial launches, regulatory…
Respiratory Today—November 7, 2025
This week’s respiratory update spotlights key developments, regulatory…